BPG is committed to discovery and dissemination of knowledge
Basic Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 14, 2025; 31(38): 109486
Published online Oct 14, 2025. doi: 10.3748/wjg.v31.i38.109486
Rutaecarpine targets F-box and WD repeat domain containing 11 to inhibit inflammatory infiltration and alleviate acute pancreatitis
Yan Jia, Yu-Xin Shi, Huan Gu, Ya Liu, Jie Peng, Lu Yan
Yan Jia, Yu-Xin Shi, Huan Gu, Ya Liu, Jie Peng, Lu Yan, Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Yan Jia, Yu-Xin Shi, Huan Gu, Ya Liu, Jie Peng, Lu Yan, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Co-first authors: Yan Jia and Yu-Xin Shi.
Author contributions: Jia Y and Shi YX contributed equally to this manuscript and are co-first authors. Jia Y and Shi YX contributed to methodology, formal analysis, and writing original draft; Jia Y and Yan L contributed to conceptualization; Jia Y, Shi YX, and Yan L contributed to writing - review and editing; Jia Y contributed to visualization; Jia Y, Peng J, and Yan L contributed to funding acquisition; Shi YX and Liu Y contributed to software; Gu H contributed to validation; Gu H and Yan L contributed to resources; Gu H and Peng J contributed to investigation; Liu Y contributed to data curation; Peng J and Yan L contributed to project administration; Yan L contributed to supervision.
Supported by Hunan Provincial Natural Science Foundation of China, No. 2022JJ40836; the Key Project of Research and Development Plan of Hunan Province, No. 2023DK2002; and the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation, No. GZC20242045.
Institutional animal care and use committee statement: The animal study protocol was approved by the Experimental Animal Ethics Committee, Xiangya Hospital, Central South University (No. 202110080).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lu Yan, MD, Department of Gastroenterology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410008, Hunan Province, China. yanluxy@csu.edu.cn
Received: May 16, 2025
Revised: June 26, 2025
Accepted: September 1, 2025
Published online: October 14, 2025
Processing time: 154 Days and 18.6 Hours
Core Tip

Core Tip: Rutaecarpine (Rut) is a major bioactive compound with a broad spectrum of pharmacological properties. Our previous study demonstrated that Rut significantly alleviated pancreatic inflammation and necrosis in acute pancreatitis (AP) rat models, primarily through a calcitonin gene-related peptide-dependent manner involving the suppression of inflammatory signaling pathways. However, given the multifactorial pathogenesis of AP and Rut’s inherent polypharmacological properties, the precise molecular mechanisms responsible for its protective effects warrant further investigation. Thus, based on the original research, this study uncovers a previously unrecognized mechanism of Rut (enhancer of zeste homolog 2-dependent F-box and WD repeat domain containing 11 suppression) and provides evidence that traditional Chinese medicine can target epigenetic reprogramming in AP.